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Abstract Chronic infection with the hepatitis C virus
(CHC) is associated with physical and mental symptoms
including fatigue and depression that adversely affect quality
of life. A related complaint, sleep disturbance, has received
little attention in the literature, with the exception of sleep
changes noted in cirrhosis and end-stage liver disease. We
present an overview of studies indicating sleep problems in
patients with CHC, with about 60% to 65% of individuals
reporting such complaints. Evidence suggests that impair-
ments in sleep quality exist independent of antiviral therapy
with interferon-α and prior to advanced stages of liver
disease. Further investigation of sleep disturbance in CHC
patients with a mild stage of liver disease may provide
important information on disease course as well as allow
additional opportunities for patient support.
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Introduction
Chronic infection with the hepatitis C virus (CHC) in the
United States is reported to have peaked at 3.6 million
Americans affected; however, the number of individuals
with advanced fibrosis is projected to continue to rise until
the year 2020 [1]. Clinical investigations of CHC have
identified decrements in physical and mental functioning
that negatively impact quality of life (QOL) [2–6]. Among
these complaints, physical tiredness or fatigue is the most
prevalent symptom endorsed by a sample of patients living
with CHC [7]. In fact, studies of CHC have shown that up
to 97% of individuals with CHC endorse fatigue [4, 6, 8]. A
study of 94 CHC patients not receiving antiviral therapy
identified predictors of fatigue to include poor social
functioning, poor physical functioning, greater depression,
and female gender [9]. Although fatigue has been widely
reported, one seemingly related factor, sleep disturbance,
has received little attention in the literature. Clinical
experience suggests that patients with CHC endorse
sleeping problems, and large studies of CHC patients
undergoing antiviral therapy with interferon (IFN)-α report
insomnia as an adverse event endorsed by as many as 30%
[10, 11]. However, the nature of sleep problems in CHC
remains poorly understood. Exploration of sleep distur-
bance in patients with CHC may provide important
information about the disease course and allow opportuni-
ties for additional supportive care of this patient group.
Sleep may be particularly important to study in light of the
recent finding that survival was strongly associated with
sleep disturbance among 156 patients with cirrhosis [12].
We hypothesized that patients with CHC report significant
sleeping complaints. Such sleeping problems may occur
prior to IFN treatment and in the absence of advanced
stages of liver disease.
Method
PubMed and Medline searches using search terms “sleep
and hepatitis C” were conducted to identify investigations
of sleep disturbance in CHC published in English over the
past 10 years (2000 to 2009). Only articles that 1) went
beyond simply mentioning the presence or occurrence of
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sleep disturbance and 2) considered sleep problems
independent of mood or other psychiatric disorders were
reviewed. Because the search revealed a small number of
articles on the specific topic of sleep and CHC and previous
work has shown that about 50% of patients with cirrhosis
reported unsatisfactory sleep [13], the search was expanded
to include search terms “sleep and cirrhosis” and “sleep and
end-stage liver disease (ESLD)” but excluded articles that
clearly focused on a specific cirrhotic patient sample that
would not include patients with CHC (eg, primary biliary
cirrhosis).
Results
Six articles [7, 14–17, 18•] met criteria for inclusion using
search terms “sleep and hepatitis C.” Nine additional
articles were identified using search terms “sleep and
cirrhosis” and “sleep and end-stage liver disease” [19–22,
23•, 24–27]. The majority of literature on sleep problems
focused on patients with cirrhosis.
Sleep and Hepatitis C
Clifford et al. [14] examined sleep disturbance, along with
depressive and anxious symptoms and cognitive functioning,
in 264 patients with HIV, 30 of whom were coinfected with
CHC. Sleep problems were investigated using the Pittsburgh
Sleep Quality Index (PSQI) [28], a 19-item self-report
questionnaire used to study sleep quality over a 1-month
interval. A global PSQI score and seven component scores
are calculated providing information on subjective sleep
quality, sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbances, use of sleeping medication, and daytime
dysfunction. Patients with both CHC and HIV reported
poorer sleep, overall, than patients with HIV only, with
significant group differences in sleep quality and marginally
significant differences in sleep disturbances. Coinfected
patients also reported significantly more depressive symp-
toms and demonstrated poorer performances on a task of
psychomotor speed and working memory than HIV-only
patients. There were no differences in anxious symptoms.
Lang et al. [7] surveyed 188 treatment-naive patients
with CHC and found that sleep problems were reported by
about 65% and were among the top 10 most prevalent
symptoms endorsed. Sleep problems were endorsed equally
as often by men as women, unlike depression, physical
tiredness, mental tiredness, and forgetfulness, which were
endorsed more frequently by women. CHC patients
additionally rated symptom severity using a visual analogue
scale (VAS) ranging from 0 to 10, with higher scores
indicating worse severity over the previous 3 months. The
median severity score for individuals reporting sleep
problems was 8 on the VAS (range 2 to 10), the highest
ranked score among the 21 symptoms reported.
Other investigations of sleep disturbances in early stages
of disease were focused on the relationship between sleep
disturbance and development of major depressive disorder
(MDD) during the course of IFN treatment [16, 17].
Researchers measured sleep problems with the PSQI and
administered a semistructured clinical interview to diagnose
MDD. Results suggested poor sleep quality is associated
with subsequent depression during IFN therapy, but
depression was not associated with changes in sleep quality
[17]. Moreover, sleep quality tended to be better in CHC
patients with a particular genotype of the serotonin
transporter length promoter region that was associated with
a lower rate of MDD, suggesting a possible mediational
role of sleep quality in resilience to MDD [16].
Given the lack of research on sleep problems in untreated
CHC patients, our group investigated sleep disturbance in 80
consecutive CHC patients seen in a tertiary hepatology clinic
[29]. All participants completed the PSQI and Fatigue
Severity Scale (FSS) [30], a nine-item self-report question-
naire measuring the impact of fatigue on daily functioning.
Information on psychiatric diagnoses and liver disease
staging were also collected. Of the 80 CHC patients sampled,
about 63% were identified as poor sleepers on the PSQI.
Fifty-six (70%) of the participants met criteria for significant
self-reported fatigue on the FSS. As expected, a significant
relationship was found between the global PSQI and FSS
scores (R=0.50, P<0.001). Further analysis revealed no
significant differences in sleep complaints endorsed by
patients with or without psychiatric diagnoses. Finally,
decrements in sleep quality did not differ according to stage
of liver disease, suggesting that sleep disturbance is not only
a function of advanced stages of liver disease.
In their review article of sleep disturbance in CHC,
Sockalingam et al. [18•] also note the paucity of research in
this area and describe in detail how to diagnose and treat
the most common sleep disorders in CHC, including
insomnia, hypersomnia, restless leg syndrome (RLS), and
obstructive sleep apnea (OSA). They also review the
literature on sleep disturbances in untreated CHC patients,
as well as IFN-induced sleep disturbances, identifying 17
articles published on this topic between 1995 and 2008.
Potential etiologies of sleep disturbance in CHC also are
discussed. However, their review did not discuss 8 of the 14
articles included in the current review [14–17, 21, 22, 23•,
24], and the current review did not discuss diagnosis and
treatment of sleep disorders.
Sleep and Cirrhosis
With regard to the articles addressing sleep in cirrhotic and
ESLD patients, much of this work viewed sleep disturbance
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as part of hepatic encephalopathy (HE), particularly
minimal HE. Martino et al. [22], for example, concluded
that sleep electroencephalogram (EEG) revealed the exis-
tence of minimal HE and that changes of mean dominant
frequency were early markers of cerebral dysfunction.
Investigators then began to examine OSA as a complication
of cirrhosis [19, 25, 26], finding that as the severity of
cirrhosis increased, so did the presence of OSA, particularly
in patients with Child-Pugh scores in class C [26].
Additionally, patients with ascites were more likely to have
OSA, which may be reversed with removal of ascitic fluid
[19]. Central sleep apnea, on the other hand, was not
observed in a small sample of patients with cirrhosis [21].
Together, these findings suggest symptoms of sleep apnea
in patients with cirrhosis may be related to an enlarged
abdominal perimeter and changes in systemic hemodynam-
ics and vasoactive systems associated with decompensated
cirrhosis, particularly ascites [19].
More recent work has focused on understanding the
qualitative aspects of sleep disturbance in patients with
cirrhosis and investigating possible treatments. Mostacci
et al. [24] reported that patients with cirrhosis complained
of significantly more frequent daytime sleepiness and
habitual napping, nighttime sleep problems, and nocturnal
awakenings than controls, which were not related to clinical
or laboratory parameters. Nighttime sleep disturbance,
daytime sleepiness, and preference for evening activities
also were noted in a study of the relationship between sleep
and QOL in 87 patients with cirrhosis [23•]. In this study,
almost 70% of patients were classified as “poor sleepers”
using the PSQI, and nighttime sleep disturbance and
evening preference were independent predictors of poorer
QOL. Montagnese et al. [23•] pointed out that nighttime
sleep disturbance and daytime sleepiness were not corre-
lated, but that daytime sleepiness was correlated with
slowing on EEG, suggesting that daytime sleepiness might
be a harbinger of minimal HE whereas nighttime sleep
disturbance does not relate to or reflect the presence of HE.
An initial study of the prevalence of RLS in a
heterogeneous sample of 141 patients with chronic liver
disease seen in an academic-based tertiary care hepatology
clinic found that 62% of respondents indicated RLS [20].
Prevalence of RLS did not differ by gender; the only
significant difference between patients with and without
reported RLS was the presence of neuropathy, which was
more commonly reported in patients with RLS. However,
16% of patients with RLS had no identifiable risk factor. In
the only treatment study of sleep disturbance in cirrhotic
patients, Spahr et al. [27] found that, compared with
placebo, hydroxyzine, 25 mg, at bedtime significantly
improved patients’ self-reported sleep disturbance assessed
using a VAS, as well as their objective sleep efficiency as
measured by wrist actigraphy. Importantly, performances on
neuropsychologic tests were not affected by administration
of hydroxyzine. However, one patient developed clinically
overt HE, which was reversed with cessation of hydroxy-
zine, indicating this medication should be used with caution
in cirrhotic patients.
Although changes in sleep behavior appear to be common
in patients with cirrhosis, the underlying mechanisms are not
yet defined and are likely multifactorial. One hypothesis
implicates abnormal liver metabolism of plasma melatonin,
which is known to play a key role in sleep [15]. Another
hypothesis suggests sleep behavior alterations may result
from dysregulation of histaminergic neurotransmission in the
brain, because histamine is involved in regulation of sleep-
wake cycles and vigilance [31]. Still another posits dysregu-
lation of serotonin and corticospinal tracts, particularly in the
etiology of RLS [20]. A more detailed review of potential
mechanisms for sleep disturbance in cirrhotic patients is
beyond the scope of this article, however.
Discussion
Literature on the nature of sleep disturbance in CHC
appears quite limited. Initial data from the few available
studies suggest a prevalence of sleep complaints of about
60% to 65% [7, 29], with a moderate relationship between
poorer sleep quality and greater fatigue [29]. Furthermore,
preliminary findings suggest that sleep problems may exist
independently of mood and other psychiatric disorders in
CHC [29] and may predict the onset of MDD in CHC
patients undergoing IFN therapy [17]. It therefore seems
prudent that clinicians monitor sleep complaints prior to
treatment, because they may have the potential to aggravate
symptoms of underlying mood or psychiatric problems, as
well as other side effects of antiviral treatment. The
literature also strongly points to the fact that sleep
disturbance exists prior to the onset of cirrhosis and ESLD,
suggesting that HE is not the only factor contributing to
sleep problems in patients with chronic liver disease.
Clearly, additional research is needed to characterize
sleep problems in noncirrhotic patients with CHC. Future
studies on the effects of CHC infection on the brain may
provide important information on the nature of sleep
disturbance reported by patients with CHC. Growing
research suggests that hepatitis C may be neurovirulent,
affecting the central nervous system via a “Trojan horse”
mechanism [32]. Studies have shown evidence of cognitive
deficits in CHC [33], and a recent review summarized
neuroimaging research on brain systems potentially affected
[34]. It is unknown whether such effects on the brain may
play a role in the sleep complaints reported by patients.
Future research may benefit from further exploration of this
potential relationship.
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In cirrhotic patients, sleep disturbance has long been
recognized as part of HE, with OSA receiving the most
attention by investigators [19, 25, 26]. Recent research has
begun to characterize qualitative aspects of sleep com-
plaints in these patients [23•, 24], with one treatment study
suggesting hydroxyzine may be of potential benefit [27].
The etiologies of sleep problems in cirrhotic and ESLD
patients are likely multifactorial, and may be related to liver
metabolism of plasma melatonin, enlarged abdominal
perimeter and associated effects, comorbid medical con-
ditions, and/or dysregulation of neurotransmitter systems
[15, 19, 20, 31].
Conclusions
In summary, considerably more research studies focused
on the role of CHC infection and sleep and its potential
effects on the brain are needed. Future research should
study patients with mild stages of disease and include
objective measures of sleep quality, such as EEG,
actigraphy, and/or polysomnography. It is important that
future research also assess for sleep quality independent
of mood and other psychiatric problems. With increased
knowledge about the mechanisms that underlie sleep
disturbance in patients with CHC, appropriate treatments
can be developed that may improve patient care out-
comes and QOL.
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